Barclays’s Aravive, Inc. Common Stock ARAV Stock Holding History

Barclays’s Portfolio ARAV Stock Details ARAV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,383	Closed	-$153K	–	7179
2017 Q3	$153K	Buy	+10,383	New	+$1.05M	﹤0.01%	4630

Other funds holding ARAV

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Barclays's ARAV Position: Q4 2021 in Review

Barclays sold out of Aravive, Inc. Common Stock (ARAV) in Q4 2021, closing a stake of 1,678 shares — an estimated $6K sold.

Barclays first reported a position in ARAV in Q2 2014 and held it in 29 quarters. The position peaked at $125K in Q3 2017. 36 funds tracked by Wall St. Rank hold ARAV as of Q4 2021.

Barclays reported no remaining Aravive, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Barclays sold 1,678 Aravive, Inc. Common Stock shares in Q4 2021, an estimated $6K.
Barclays first reported a position in Aravive, Inc. Common Stock in Q2 2014 and held it in 29 quarters.
Barclays's Aravive, Inc. Common Stock position peaked at $125K in Q3 2017.
36 funds tracked by Wall St. Rank held Aravive, Inc. Common Stock as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.